$99.2MSeries B, 10 July 2025
Series B to advance clinical development of its copper-based theranostic pipeline and expand manufacturing.
- Amount
- $99.2M
- Stage
- Series B
- Announced
- 10 July 2025
- Lead
- Kurma Growth Opportunities Fund
- Other investors
- Angelini Ventures, Wellington Partners, Neva SGR, DeepTech & Climate Fonds, Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK, HighLight Capital
- Use of funds
- Series B to advance clinical development of its copper-based theranostic pipeline and expand manufacturing.
- Checked
- Announced by the company
- Sources
- Angelini Ventures co-leads Nuclidium EUR 84M Series B wellington-partners.com
Angelini Ventures co-leads Nuclidium EUR 84M Series B startupbusiness.it